Switch to Anabolics Driving Osteoporosis Market Growth

Monday 24 February 2014, Amsterdam

A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic drugs will prove the key driver in the global osteoporosis market.

The new report* forecasts that the combined osteoporosis therapeutics market of the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, China, and India  will reach a value of US$8 billion in 2022 from just under US$6 billion in 2012, including both branded and generic products.

Six major osteoporosis drugs will lose patent protection over the forecast period, which would strangle market growth if it were not for the introduction of several anabolic alternatives with the potential to become market leaders.  

Three late-stage pipeline products, romosozumab, BA-058, and oral PTH, have been found to be highly efficacious - sometimes increasing Bone Mineral Density (BMD) by double that achieved by current treatment options. In particular, Romosozumab, Amgen and UCB‘s hugely promising novel anti-sclerostin mAb, is expected to reach revenue of US$905m in 2022, following its anticipated launch in 2016.

Furthermore, there are a number of exciting earlier stage pipeline products from companies including Eli Lilly and Radius Health promising to boost revenue and reinforce the emergence of anabolics as the disease area’s key growth driver.

The new report expects the US to further solidify domination of the global osteoporosis therapeutics market over the following decade, with revenue expected to creep up from US$2.7 billion in 2012 to US$3.9 billion in 2022 – expanding the nation’s share of the global market from 46% to 48%.